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Abstract
Background: Fibroblast growth factor 21 (FGF21) is a hepatic hormone involved in the regulation of lipid and carbohydrate
metabolism. This study aims to test the hypothesis that elevated FGF21 concentrations are associated with the change of
renal function and the presence of left ventricular hypertrophy (LVH) in the different stages of chronic kidney disease (CKD)
progression.
Methodology/Principal Findings: 240 subjects including 200 CKD patients (146 outpatients and 54 long-term hemodialytic
patients) and 40 healthy control subjects were recruited. All CKD subjects underwent echocardiograms to assess left
ventricular mass index. Plasma FGF21 levels and other clinical and biochemical parameters in all subjects were obtained
based on standard clinical examination methods. Plasma FGF21 levels were significantly increased with the development of
CKD from early- and end-stage (P,0.001 for trend), and significantly higher in CKD subjects than those in healthy subjects
(P,0.001). Plasma FGF21 levels in CKD patients with LVH were higher than those in patients without LVH (P=0.001).
Furthermore, plasma FGF21 level correlated positively with creatinine, blood urea nitrogen (BUN), b2 microglobulin, systolic
pressure, adiponectin, phosphate, proteinuria, CRP and triglyceride, but negatively with creatinine clearance rate (CCR),
estimated glomerular filtrate rate (eGFR), HDL-c, LDL-c, albumin and LVH after adjusting for BMI, gender, age and the
presence of diabetes mellitus. Multiple stepwise regression analyses indicated that FGF21 was independently associated
with BUN, Phosphate, LVMI and b2 microglobulin (all P,0.05).
Conclusion: Plasma FGF21 levels are significantly increased with the development of early- to end-stage CKD and are
independently associated with renal function and adverse lipid profiles in Chinese population. Understanding whether
increased FGF21 is associated with myocardial hypertrophy in CKD requires further study.
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Introduction
Chronic kidney disease (CKD) is a growing public health
concern that is associated with a markedly increased risk of
cardiovascular disease and mortality[1,2]. Although many tradi-
tional risk factors for atherosclerosis such as hypertension and
diabetes mellitus promote the progression of CKD from early- to
end-stage, these classic risk factors do not fully account for the
burden of cardiovascular disease in patients with CKD[3,4]. Left
ventricular hypertrophy (LVH) is one of several common
manifestations of cardiovascular disease that is a major indepen-
dent risk factor for mortality in patients with CKD[3,4]. Exploring
the early mechanism of LVH is necessary to develop therapies that
block the progression of CKD and attenuate cardiovascular
disease associated with CKD.
The fibroblast growth factor family is composed of 22 members
with a wide range of biological functions, including cell growth,
development, angiogenesis, and wound healing[5–9]. FGF21 is a
member of the endocrine FGF subfamily, which also includes
FGF23, human FGF19, and its mouse homolog FGF15[10–14].
In mice, FGF21 is expressed predominantly in the liver and
stimulates glucose uptake through the induction of GLUT1 in
adipocytes[13]. In vivo treatment with FGF21 results in
amelioration of glucose and regulates lipid metabolism in both
murine and nonhuman primate models of diabetes and obesi-
ty[15–17]. Taken together, these findings demonstrate an
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lipid metabolism and also suggest that FGF21exhibits the
therapeutic characteristic necessary for an effective treatment of
obesity and fatty liver disease.
Human studies indicate that circulating levels of FGF21
increased in obese individuals [18], subjects with metabolic
syndrome, type 2 diabetes mellitus[19–21] and coronary heart
disease[22]. Furthermore, FGF21 was found to closely associated
with renal dysfunction in end-stage renal disease subjects[23,24].
On the other hand, previous studies indicated that FGF receptors,
particularly FGFR1, are expressed in adult myocardial cells, and
their activation by locally secreted growth factors can stimulate
myocardial hypertrophy and interstitial fibrosis[25,26]. For
example, mice lacking FGF-2 exhibit dilated cardiomyopathy
and impaired hypertrophic responses to angiotensin II[27], and
adenoviral Gene Transfer of FGF-5 to Hibernating myocardium
improves function and stimulates myocytes to hypertrophy and
reenter the cell cycle[26]. Recently, FGF-23, one member of FGF-
19 subfamilies, was reported to associate with the onset and
development of CKD[28–30] as well as LVH in patients with
CKD[31]. Take together, all these reports suggested that FGF
family members play an important role in the physiopathology of
LVH. Whether FGF21, however, is closely associated with the
pathological relevance of CKD and LVH in CKD patients remain
unclear. To explore the physiological and pathological relevance
of FGF21 in patients with CKD, we measured the plasma
concentrations of FGF21 in 240 Chinese subjects and analyzed its
association with renal function and a cluster of metabolic
parameters that related to the change of renal functions.
Materials and Methods
Study Population
The study population consisted of 146 outpatients with CKD
and 54 CKD patients with long-term hemodialysis. 146 patients
with CKD were recruited from outpatient nephrology clinics at
the Second Affiliated Hospital of Wenzhou Medical College,
Wenzhou. Patients recruited into this study were $25 years of age
and had a sustained reduction ($3 months) in estimated
glomerular filtration rate (eGFR) #60 ml ? min
21 ? 1.73 m
-2
based on the simplified Modification of Diet in Renal Disease
formula. Patients with preserved eGFR ($60 ml/min per
1.73 m
2) were also considered as early stage CKD patients if they
presented with one or more of the following related symptoms:
persistent hematuria and/or proteinuria with biopsy-proven
minimal-change disease, membranoproliferative glomerulonephri-
tis, or other relevant nephropathies. 54 CKD patients with long-
term hemodialysis (eGFR,15 ml ? min
21 ? 1.73 m
22) were also
recruited into the present study. These subjects with long-term
hemodialysis were recruited from inpatient services at the
Hemodialytic Center of the 2
nd Affiliated Hospital of Wenzhou
Medical College and were scheduled for an echocardiogram for
diagnostic purposes by the primary admitting team. Patients were
at least 25 years of age and clinically stable and did not have acute
myocardial infarction, known cardiomyopathy or ejection fraction
, 40%, or known mitral or aortic valve disease. Exclusion criteria
included kidney transplant, history of coronary artery bypass
grafting, or an incidence of myocardial infarction within 90 days of
enrollment. In addition, to focus on patients with early cardiac
disease, patients surpassing criteria for New York Heart Associ-
ation class 1 heart failure or Canadian Cardiovascular Society
class 1 angina were excluded. The comorbidities including
diabetes and hypertension were defined on basis of the clinical
diagnosis criteria of WHO and American Diabetes Association or
American Society of Hypertension respectively. We also included
healthy controls (n=40) who underwent a routine health
examination at 2nd Affiliated Hospital of Wenzhou Medical
College, had no history of medical disease, and were not taking
regular medication, all control subjects were selected based on the
results of physician’s questionnaire and clinical biochemical
examination. All studies were approved by the Ethics Committee
of Wenzhou Medical College, and all patients provided written
informed consent.
Clinical Data and Laboratory test
Data on demographic characteristics, medical history, current
medications, and blood samples were collected from all subjects
at the time of enrollment. Blood was collected from subjects after
overnight fasting for at least 10 h. Blood samples were
immediately centrifuged, separated into aliquots, and stored at
280uC for future batched assays. Serum creatinine, calcium,
phosphate, and albumin were measured with standard commer-
cial assays. Intact parathyroid hormone concentrations were
measured with the Roche Elecsys parathyroid hormone assay
(Roche, Indianapolis, Ind). Plasma FGF21 (Biovendor, Modrice,
Czech Republic) and C-reactive protein (CRP, R&D, USA)con-
centrations and were measured in duplicate with commercially
available enzyme-linked immunosorbent assays according to the
manufacturers’ instructions in the Core Laboratory of School of
Pharmacy, Wenzhou Medical College. All other blood tests in
CKD subjects were processed in Clinical Examination Labora-
tory of the 2
nd Affiliated Hospital of Wenzhou Medial College
after a single thaw.
Echocardiography
All subjects underwent 2-dimensional transthoracic echocardio-
grams. The studies were interpreted by a single reviewer at the 2
nd
Affiliated Hospital of Wenzhou Medial College who was blinded
to subjects’ clinical and laboratory data. For the primary analysis,
leftventricularmass index (LVMI) was calculated with the Devereux
formulation[32,33]: Left ventricular hypertension (LVH) was
defined as LVMI .135 g/m
2 for men and .110 g/m
2 for women
in Chinese population[34]. Left ventricular ejection fraction (LVEF)
was determined using biplane-modified Simpson’s measurements.
Statistical analysis
All analyses were performed with Statistical Package for Social
Sciences version 13.0 (SPSS,Chicago, IL), and the statistical
analysis was done similarly as described by Zhang X et al[18]. In
brief, normally distributed data were expressed as mean6SD.
Data that were not normally distributed, as determined using
Kolmogorox-Smirnov test, were logarithmically transformed
before analysis and expressed as median with interquartile range.
Student’s unpaired t test was used for comparison between two
groups. Pearson’s correlations were used as appropriate for
comparisons between groups, and multiple testing was corrected
using Bonferroni correction. Linear regression was used to
examine the association between LVMI, LVH, CRP and other
clinical, and laboratory variables. We used multivariable models to
examine the relationship between LVMI and FGF21 concentra-
tions, adjusting for age, gender, body mass index (BMI), diabetes
mellitus, hypertension that were significantly (P,0.05) associated
with LVMI in univariate analyses. The variables that correlated
significantly with serum FGF21 (after Bonferroni correction for
multiple testing) were selected to enter into multiple linear
regression. In all statistical tests, P values ,0.05 were considered
significant.
FGF21 and Chronic Kidney Disease
PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e18398Results
Patient Characteristics
Table 1 depicts demographic information, laboratory data and
echocardiogram results of the 200 CKD subjects according to level
of kidney function and 40 normal control subjects. CKD patients
were divided into three groups according to the eGFR, namely
early-stage group (preserved renal function, eGFR 60 to 90 ml/
min per 1.73 m
2), middle-stage group (eGFR 30 to 60 ml/min per
1.73 m
2) and end-stage group (hemodialytic group, eGFR
,30 ml/min per 1.73 m
2). 55 patients with preserved eGFR
(.90 ml/min per 1.73 m
2) were also considered as CKD patients
(early stage) based on the recruitment standards shown in the
Materials and Methods section. Furthermore, relevant biochem-
ical and anthropometric parameters in 40 healthy subjects were
shown in Table 1. The results of echocardiography and its relevant
parameters in normal subjects were not examined in this study,
because all these subjects recruited into the present study were
underwent a routine health examination, and had no history of
disease, and were not taking regular medication based on the
results of physician’s questionnaire and clinical biochemical
examination.
Plasma FGF21 levels are increased in CKD patients
Plasma FGF21 levels rangedfrom 67.4 to 7232.6 pg/ml amongst
subjects in this study, and the median FGF21 concentration in
overall subjects was 616.1 pg/ml (interquartile range, 264.4 to
1137.8 pg/ml). No gender differences in plasma FGF21 levels were
Table 1. Description of Subjects by Level of Kidney Function.
Variables Normal subjects
Early-stage eGFR .60
ml/min per 1.73 m
2
Middle-stage eGFR(30–60)
ml/min per 1.73 m
2
End-stage eGFR ,30
ml/min per 1.73 m
2 P for trend
N4 0 7 6 3 6 8 8 -
Age(years) 49.5612.3 50.7615.0 50.7617.3 50.6610.0 NS
Women(%) 14(32.5) 25(32.8) 12(33.3) 28(31.8) NS
BMI(kg/m
2)2 1 62.5 2363.3 23.863.6 2162.9 ,0.001
Hypertension
Systolic blood press 104618 136624 149628 150631 ,0.001
Diastolic blood press 69611 84617 88614 85619 ,0.001
The presence of hypertension - 36.8 55.6 50.0 NS
Glucose
fasting glucose 5.0860.56 4.9961.37 4.5961.02 7.5964.52 ,0.001
fasting insulin 4.16(3.01–6.17) 7.62(4.96–11.37) 13.82(8.06–30.95) 12.99(5.08–23.16) ,0.001
HOMA-ir 0.92(0.63–1.44) 1.31(0.77–2.27) 4.63(2.47–5.34) 3.58(1.04–7.26) ,0.001
The presence of diabetes - 19.7 33.3 46.6* ,0.001
Lipid profiles
TG 0.9260.38 2.0561.20 1.9761.37 1.9361.49 0.004
LDL 2.5760.46 3.3061.60 3.3061.23 2.2660.46 ,0.001
HDL 1.3960.25 1.1560.50 1.0960.40 0.9460.31 ,0.001
Laboratory values
CCR 81.2613.5 66.2627.5 28.2610.7 7.563.5 ,0.001
Albumin(g/l) 48.766.7 30.468.8 28.867. 4 30.964.6 ,0.001
Creatinine(mmol/l) 65.8611.0 103.9639.3 243.6647.5 811.36293.3 ,0.001
Calcium (mmol/l) 2.2860.32 2.1360.17 2.1660.12 2.1960.21 NS
phosphate(mmol/l) 1.2460.26 1.2660.22 1.3660.16 1.7860.61 ,0.001
PTH(pg/ml) 42.3617.0 76.7626.0 97.6664.7 469.06470.0 ,0.001
BUN(mmol/l) 4.161.04 6.3562.67 12.2864.58 21.4467.51 ,0.001
Uric Acid(mmol/l) 286651 388698 4316118 4436120 ,0.001
CRP(mg/ml) 0.1860.16 0.7160.53 1.1761.29 2.0261.68 ,0.001
b2 microglobulin(mg/ml) 1.5160.32 2.6261.09 5.9061.24 15.5069.87 ,0.001
Adiponectin(mg/ml) 2.1060.78 2.2660.65 2.5860.59 3.2661.17 ,0.001
FGF21(pg/ml) 127.6(85.7 to 218.4) 317.1(209.9 to 732.8) 517.1(220.3 to 912.0) 1098.8(523.1 to 2467.8) ,0.001
Echocardiography
LVMI(g/m
2)-
# 100.6621.7 112.3614.7 136.6639.7 ,0.001
LVH,% -
# 12.0 28.6 53.7 ,0.001
EF,% -
# 66.763.5 64.466.5 62.865.9 ,0.001
NS: not significant. Results are expressed as frequencies, mean6SD, or median (interquartile range) as appropriate.
*Percentage of type 2 diabetes mellitus in end-stage CKD patients is significantly higher than those CKD patients in early-and middle-stage.
doi:10.1371/journal.pone.0018398.t001
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(789.6686.5 pg/ml, n=85; p=0.470). After adjusting for age,
gender, and body mass index (BMI), median circulating FGF21
level in end-stage CKD patients (1447.96146.5 pg/ml) was 10-
fold higher compared with normal subjects (147.3612.25 pg/ml;
P,0.0001); and about 3.5-fold higher compared with the early-
stage CKD patients (402.9635.0 pg/ml; P,0.0001), and about
1.5-fold higher compared with the middle-stage CKD patients
(845.86238.7 pg/ml; P,0.0001; Figure 1). Interestingly, CKD
patients recruited into this study with diabetes mellitus (DM)
(12536170.1 pg/ml, n=68) had significantly higher plasma
FGF21 levels (P=0.0016) than those without DM (7146
82.1 pg/ml, n=132). On the other hand, no significant
difference in plasma FGF21 levels was observed between all
CKD patients with and without hypertension (P=0.7730), as well
with and without CHD (P=0.6563). Furthermore, all CKD
subjects with other comorbidities including DM, hypertension
and CHD in this study had significantly higher plasma FGF21
levels (14226302.9 pg/ml, n=9) than those without correspond-
ing comorbidities (611.26111.5 pg/ml, n=55, p=0.0091).
FGF21 and left ventricular structure
LVMI values in all CKD subjects of this study ranged from
49.02 to 247.99 g/m
2 with mean LVMI at 118.5 g/m
2 and 31.7%
of patients experiencing left ventricular hypertrophy. Compared
with early- and middle-stage CKD patients, however, patients with
end-stage CKD had significantly higher mean LVMI(110.3 6
28.7 vs. 132.8 6 36.1 g/m
2) and lower mean ejection frac-
tion(67.9763.40 vs. 63.3364.97%). Mean LVMI and the
prevalence of LVH (31.7%) among CKD subjects in this study
were lower than in previous studies[35,36] confirming that the
majority of patients recruited for this study were free of significant
cardiac disease, consistent with the study design. Furthermore,
CKD patients with hypertension showed a higher LVMI value
than those without hypertension (124.9634.8 vs.110.9632.8,
P=0.006).
To explore the relationship between FGF21 and ventricular
structure, we compared the levels of FGF21 in the CKD patients
with and without LVH. Plasma FGF21 levels in CKD patients
with LVH (median 923.9 pg/ml, interquartile 363.7 to
1478.7 pg/ml) were significantly higher than those without LVH
(median 446.5 pg/ml, interquartile 245.6 to 953.1 pg/ml;
P=0.001; Figure 2A).
In univariable analyses, increased log FGF21 concentrations
were significantly associated with increased LVMI (P=0.007;
Figure 2B). When adjusted for age, gender, BMI, diabetes mellitus,
no significant association was found between log FGF21and log
LVMI (P=0.091). In the multivariable model, BMI, systolic
pressure and LVH were the only three parameters that remained
Figure 1. Plasma FGF21concentration in different stage of CKD
subjects and normal subjects.
doi:10.1371/journal.pone.0018398.g001
Figure 2. The relationship between FGF21 and LVH. A, circulating levels of FGF21 in CKD patients with LVH were significantly higher than that
of CKD subjects without LVH; B, correlation between log-transformed FGF21 and LVMI. # indicates outpatients (early-and middle-stage CKD
patients); N hemodialytic patients (end-stage CKD patients).
doi:10.1371/journal.pone.0018398.g002
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Furthermore, when examined in tertiles, mean LVMI increased
with increasing tertiles of log FGF21(P=0.005 for trend; Table 2).
On the other hand, in univariable analyses, increasing log
FGF21 concentration was also significantly associated with the
presence of LVH (odd ratio[OR] per 1-SD increase in log FGF21,
0.381; 95% confidence interval [CI], 0.214 to 0.68; P=0.001).
When adjusted for age, gender, BMI, hypertension, diabetes
mellitus, log FGF21 was still significantly associated with the
presence of LVH (OR per 1-SD increase in log FGF21, 0.422;
95% CI, 0.218 to 0.817; P =0.010). Furthermore, the prevalence
of LVH increased significantly with ascending tertiles of log
FGF21 in univariable analyses (Table 2), but this relationship was
attenuated after multivariable adjustment.
FGF21 and Phosphate Concentrations
Hyperphosphatemia with serious inflammatory reaction is a
common manifestation of CKD. As shown in Table 3, circulating
levels of FGF21 were found to strongly correlate with serum
phosphate, creatine and CRP levels in CKD subjects after
adjustment for BMI, gender, age and diabetes mellitus. Further-
more, mean FGF21, phosphate and creatinine concentrations
were significantly increased with decreasing levels of eGFR(P for
trend ,0.001 for both). However, the absolute difference in mean
serum phosphate concentration between normal subjects and
early-stage CKD patients was about 0.01 mmol/l (relative
difference, increasing 0.8%, P=0.727; Figure 3A); Furthermore,
the absolute difference in mean serum creatinine levels between
normal subjects and early-stage CKD patients was about
38.1 mmol/l (relative difference, increasing 57.8%, P,0.001;
Figure 3B). In contrast, the absolute difference in mean FGF21
concentration between normal subjects and early-stage CKD
group was 245 pg/ml (relative difference, increasing 1.5-fold,
P,0.001). Additionally, a significant difference in FGF21
concentration was found between early-and middle-stage
CKD patients (402.4649.6 vs. 904.66262.0 pg/ml; P=0.0014;
Figure 1A).
Plasma FGF21 levels strongly associated with renal
function, adverse lipid profiles and other factors in all
CKD subjects
As shown in Table 3 and Figure 4, plasma FGF21 levels were
strongly correlated with eGFR, endogenous creatinine clearance
rate (CCR), creatinine and BUN, suggesting that elevated FGF21
concentrations were closely associated with the renal function in
these CKD subjects. On the other hand, plasma FGF21 levels
were associated with adverse lipid profiles including HDL-c, LDL-
c and triglyceride (all P,0.05) after adjustment for age, gender,
BMI and diabetes mellitus in all CKD subjects. Furthermore,
systolic pressure, adiponectin, proteinuria, b2 microglobulin,
phosphate, albumin and LVH were significantly correlated with
circulating FGF21 levels after adjustment for BMI, gender age and
diabetes mellitus in all CKD subjects.
Table 2. Echocardiographic characteristics and relevant interesting factors by tertile of log FGF21.
variable Log FGF21(, 2.5) Tertile 1 Log FGF21 (2.5 to 3.0) Tertile 2 Log FGF21 (.3.0) Tertile 3 P for trend
N 52 51 82 -
LVMI,(g/m
2) 109632 119631 127635 0.004
LVH, % 21 34 46 0.006
Phosphate(mmol/l) 1.4060.42 1.4660.45 1.6560.63 0.007
CRP(mg/ml) 0.62(0.22–1.28) 0.89(0.82–1.82) 1.47(0.71–3.45) , 0.001
Results are expressed as mean6SD, frequencies (%) and median (interquartile) as appropriate.
doi:10.1371/journal.pone.0018398.t002
Table 3. Correlations of serum FGF21 levels with
anthropometric parameters, biochemical indexes as well as
other relevant factors.
Variables Plasma FGF21
# Plasma FGF21
# *
rp rp
Gender -0.201 0.004 - -
BMI -0.158 0.026 - -
Age 0.186 0.035
Diabetes -0.310 ,0.001 - -
Systolic pressure 0.255 ,0.001 0.243 0.001
CCR
# -0.503 ,0.001 -0.349 ,0.001
eGFR
# -0.469 ,0.001 -0.341 ,0.001
BUN
# 0.413 ,0.001 0.306 ,0.001
Creatinine
# 0.513 ,0.001 0.412 ,0.001
CRP 0.271 ,0.001 0.178 0.013
Adiponectin 0.221 0.008 0.220 0.009
CXCL16 0.24 0.001 0.134 NS
TG 0.147 0.013 0.153 0.015
Cholesterol -0.151 0.011 -0.095 NS
HDL-c -0.250 ,0.001 -0.189 0.003
LDL-c -0.250 ,0.001 -0.158 0.012
Proteinuria 0.318 0.001 0.302 0.001
Fasting glucose 0.263 ,0.001 0.165 0.009
Albumin -0.165 0.019 -0.145 0.047
b2 microglobulin 0.850 ,0.001 0.930 ,0.001
Phosphate 0.288 ,0.001 0.261 ,0.001
LVDd 0.194 0.024 0.171 NS
LVMI 0.221 0.008 0.113 NS
LVH -0.217 0.001 -0.174 0.009
#Log transformed before analysis;
*adjusted by age, gender, BMI and diabetes; NS, not significant; CCR:
endogenous creatinine clearance rate; IVSTd, left ventricular end-systolic
dimension; LVDd: left ventricular diastolic dimension; LVMI: left ventricular mass
index; LVH: left ventricular hypertrophy.
doi:10.1371/journal.pone.0018398.t003
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microglobulin, LVMI, and Diabetes Mellitus
To determine whether plasma FGF21 was independently
associated with anthropometric parameters and other relevant
factors, multiple stepwise regression analysis involving all the
parameters with significant correlations with plasma FGF21 was
performed. Multiple stepwise regression analysis revealed that
plasma FGF21 was independently associated with BUN, Phos-
phate, LVMI and b2 microglobulin adjustment for age, gender
and BMI in all CKD subjects (P#0.043, respectively, Table 4),
thus all other parameters including gender, BMI, diabetes, systolic
pressure, CCR, eGFR, creatinine, BUN, CRP, adiponectin,
CXCL16, triglyceride, total cholesterol, LDL, HDL, proteinuria,
fasting glucose, albumin, LVDd and LVH were excluded during
regression analysis.
Discussion
Although several clinical studies focusing on FGF21 and its
relevant human diseases have been reported in recent years[18–
24], the definitive mechanism of FGF21 is not fully understood. In
the present study, we investigated (1) the clinical correlation of
circulating FGF21 in conjunction with physiological and patho-
logical aspects in CKD patients, (2) the relationship between the
change of circulation FGF21 levels and the development of CKD
from early- to end-stage of disease, and (3) the effect of
comorbidities of CKD to plasma FGF21 concentration. Our
results suggest that FGF21 is involved in the development of CKD
as supported by two novel findings. First, plasma FGF21
concentration is increased with the development of CKD from
early- to end-stage following the loss of renal function. Second,
relevant comorbidities including DM, hypertension and CHD in
CKD patients affected plasma FGF21 concentration. Further-
more, plasma FGF21 levels in CKD patients are significantly
correlated with adverse lipid profiles and LVH, but not with
LVMI after adjustment for age, gender, BMI and diabetes.
Previous studies indicated that serum FGF21 concentration was
15-fold higher in chronic hemodialytic patients (CKD end-stage)
than normal subjects and was associated significantly with the loss of
renal function[24]. More recently, a cross-sectional study also
indicated that serum FGF21 concentration was associated with
residual renal function and insulin resistance in end-stage CKD
patients with long-term hemodialysis[23]. These results suggested
that FGF21 may be related to renal excretion functions in humans.
Consistent with these reports, we show that plasma FGF21
concentration is increased with the development of early- to end-
stage CKD following the loss of renal functions in CKD patients.
Our data indicated that plasma FGF21 levels in end-stage CKD
patients are about 10-fold higher compared with normal subjects
(Figure 1). Furthermore, plasma FGF21 levels in end-stage CKD
patients are about 4.5-fold higher compared with the early-stage
CKD patients; and about 1.5-fold highercompared with the middle-
stage CKD patients (Figure 1). These results suggest that circulating
FGF21 concentration is associated with the CKD progression.
Diabetes contributes to increased morbidity and mortality in
patients with chronic kidney disease[37]. Diabetes is the single
leading cause of kidney failure in the U.S., accounting for about
45% of people who start treatment for kidney failure each
year[38]. In the present study, we found that diabetes has
additional effects on FGF21 levels in CKD patients, which are
supported by the fact that plasma FGF21 levels in CKD
individuals with DM were significantly higher than those CKD
patients without this complication (Figure 1B). Furthermore,
stepwise logistic regression analysis revealed that plasma FGF21
was independently associated with diabetes. Take together, these
results suggest that plasma FGF21 levels in CKD subjects are
affected by relevant comorbidities s and as on.
Hyperphosphatemia with serious inflammatory reaction is a
common manifestation of CKD, and has been shown to be
significantly associated with FGF-23, one of members of FGF
family[28,39]. In the present study, we found that elevated FGF21
levels were associated with increasing serum phosphate and CRP
levels. The relative difference in mean serum phosphate
concentration between normal subjects and early-stage CKD
patients was significantly lower than that of plasma FGF21 levels
(relative difference, 0.8% vs.150%). These results suggest that
FGF21 is a better biomarker than blood phosphate to reflect the
progression of CKD from the early-to middle stage.
Left ventricular hypertrophy (LVH) is one of several common
manifestations of cardiovascular disease and is an independent risk
Figure 3. The change tendency of serum phosphate and creatinine according to the level of eGFR in 240 Chinese subjects. Bars
represent SDs.
doi:10.1371/journal.pone.0018398.g003
FGF21 and Chronic Kidney Disease
PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18398factor for mortality in patients with CKD[3,4]. Previous studies
showed that approximately 40% of patients with pre-dialysis CKD
and up to 80% of patients initiating hemodialysis manifest
LVH[4,36]. Furthermore, FGF-23, one member of the FGF-19
subfamilies, was shown to associated with LVH in patients with
CKD[31]. In the present study, the prevalence of LVH (39.7%)
Figure 4. Correlation of plasma level of FGF21(log transformed) with CCR(A), eGFR(B), Creatinine(C), BUN(D), HDL-c(E) and
Triglyceride(F) after adjustment for age, gender, BMI and diabetes in 240 Chinese subjects.
doi:10.1371/journal.pone.0018398.g004
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because the majority of patients recruited for this study were free
of significant cardiac disease. Furthermore, our data indicated that
CKD patients with hypertension have a higher LVMI level than
those of patients without hypertension, suggesting hypertension
lead to an increase in the percentage of LVH. However, no
significant difference in plasma FGF21 level was found between
CKD patients with and without hypertension. These results
indicated that hypertension can lead to increase LVMI levels but
do not affect circulating levels of FGF21 in CKD patients.
Previous clinical studies indicated that the plasma lipid profile
frequently evolves during the course of progression of CKD, and
dyslipidemia is a strong predictor of myocardial infarction in
sujects with CKD[40,41]. Patients with mild to moderate CKD,
especially those with significant proteinuria, commonly exhibit
hypercholesterolemia and elevated LDL levels[42]. Serum triglyc-
erides and very low-density lipoprotein (VLDL) levels are elevated,
and clearance of VLDL and chylomicrons and their atherogenic
remnants is impaired in patients with advanced CKD or end stage
renal disease (ESRD)[42,43]. In present study, our data showed
that elevation of FGF21 are significantly correlated with adverse
lipid profiles including elevating LDL and triglyceride, as well as
decreasing HDL after adjustment for age, gender, BMI and
diabetes suggesting that the elevation of circulating FGF21 levels
may be directly or indirectly linked to the progression of
pathophysiology of CKD.
eGFR, CCR, creatinine and BUN are conventional biomarkers
reflecting the change of renal function[2,30]. Recent studies
indicated that serum levels of cystatin C and b2 microglobulin (b2
MG) as well as urinary b2 MG and N-acetyl-b-Dglucosaminidase
(NAG) increase in patients with early and mild renal impair-
ment[44–47]. In the present study, our data indicated that plasma
FGF21 levels are independently associated with b2 microglobulin,
and were significantly associated with eGFR, CCR, creatinine and
BUN in CKD subjects(Figure 4), suggesting that elevated FGF21
levels are closely related to the injury of glamorous and the change
of renal function in CKD patients. However, the mechanisms
responsible for the elevation of FGF21 concentration with the
progression of CKD are not fully understood. FGF21 is expressed
predominantly in liver and adipose tissue[13], and plays an
important role in regulating lipid and energy metabolism[15,48].
We speculated that the paradoxical increase in CKD patients is a
compensatory mechanism to counteract metabolic stress. Because
FGF21 resistance might be found in obesity and in renal failure,
leading to compensatory upregulation of this hepatokine[18,24].
Based on these findings, we propose that the mechanism of
increased FGF21 levels in kidney disease is similar to those
observed in obesity-associated resistance to insulin. Further studies
are needed to elucidate the precise mechanism by which CKD
subjects elevate circulating FGF21 levels and to reveal the role of
increased FGF21 levels in the onset and development of CKD.
In summary, this study provides clinical evidence revealing that
plasma concentrations of FGF21 are increased with CKD
progression and are independently associated with the loss of
renal function. There are several limitations in this study. The
sample size of this study cohort is relatively small. Furthermore,
the cross-sectional natures of this study do not allow us to address
the causal relationship between FGF21 and the development of
CKD in patients. Further prospective studies with larger sample
sizes are needed to determine whether FGF21 is related to
myocardial hypertrophy in patients with CKD.
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